RU2008122550A - Композиции и способы индуцирования активации незрелых моноцитарных дендритных клеток - Google Patents
Композиции и способы индуцирования активации незрелых моноцитарных дендритных клеток Download PDFInfo
- Publication number
- RU2008122550A RU2008122550A RU2008122550/13A RU2008122550A RU2008122550A RU 2008122550 A RU2008122550 A RU 2008122550A RU 2008122550/13 A RU2008122550/13 A RU 2008122550/13A RU 2008122550 A RU2008122550 A RU 2008122550A RU 2008122550 A RU2008122550 A RU 2008122550A
- Authority
- RU
- Russia
- Prior art keywords
- dendritic cells
- csf
- contacting
- agent
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 39
- 230000001939 inductive effect Effects 0.000 title claims abstract 7
- 230000004913 activation Effects 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 210000004443 dendritic cell Anatomy 0.000 claims abstract 74
- 239000003795 chemical substances by application Substances 0.000 claims abstract 35
- 239000000758 substrate Substances 0.000 claims abstract 20
- 239000000427 antigen Substances 0.000 claims abstract 18
- 102000036639 antigens Human genes 0.000 claims abstract 18
- 108091007433 antigens Proteins 0.000 claims abstract 18
- 230000024245 cell differentiation Effects 0.000 claims abstract 16
- 230000035800 maturation Effects 0.000 claims abstract 14
- 210000004027 cell Anatomy 0.000 claims abstract 11
- 230000004069 differentiation Effects 0.000 claims abstract 7
- 239000002243 precursor Substances 0.000 claims abstract 6
- 238000000338 in vitro Methods 0.000 claims abstract 4
- 230000003213 activating effect Effects 0.000 claims abstract 3
- 238000012258 culturing Methods 0.000 claims abstract 3
- 239000001963 growth medium Substances 0.000 claims abstract 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 28
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 28
- 102000004388 Interleukin-4 Human genes 0.000 claims 28
- 108090000978 Interleukin-4 Proteins 0.000 claims 28
- 102000003816 Interleukin-13 Human genes 0.000 claims 14
- 108090000176 Interleukin-13 Proteins 0.000 claims 14
- 102000003812 Interleukin-15 Human genes 0.000 claims 14
- 108090000172 Interleukin-15 Proteins 0.000 claims 14
- 210000001519 tissue Anatomy 0.000 claims 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 102000008070 Interferon-gamma Human genes 0.000 claims 6
- 108010074328 Interferon-gamma Proteins 0.000 claims 6
- 229960003130 interferon gamma Drugs 0.000 claims 6
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000013592 cell lysate Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010073131 oligoastrocytoma Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2313—Interleukin-13 (IL-13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74888505P | 2005-12-08 | 2005-12-08 | |
| US60/748,885 | 2005-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008122550A true RU2008122550A (ru) | 2010-01-20 |
Family
ID=38123555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008122550/13A RU2008122550A (ru) | 2005-12-08 | 2006-12-08 | Композиции и способы индуцирования активации незрелых моноцитарных дендритных клеток |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20080254537A1 (https=) |
| EP (3) | EP1957634A4 (https=) |
| JP (7) | JP5954918B2 (https=) |
| KR (6) | KR20080109717A (https=) |
| CN (2) | CN101336291A (https=) |
| AR (1) | AR056851A1 (https=) |
| AU (1) | AU2006321794A1 (https=) |
| BR (1) | BRPI0619499A2 (https=) |
| CA (1) | CA2632263C (https=) |
| CR (1) | CR10048A (https=) |
| IL (2) | IL191930A (https=) |
| RU (1) | RU2008122550A (https=) |
| TW (1) | TW200800252A (https=) |
| WO (1) | WO2007067782A2 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2950109C (en) | 2000-10-27 | 2019-02-19 | John W. Hadden | Vaccine immunotherapy for immune suppressed patients |
| US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| ES2430389T3 (es) * | 2008-04-14 | 2013-11-20 | Irx Therapeutics, Inc. | Procedimiento modificado de fabricación de IRX-2 |
| US8728806B2 (en) | 2008-12-06 | 2014-05-20 | The Board Of Regents, The University Of Texas System | Methods and compositions related to Th-1 dendritic cells |
| WO2010115229A1 (en) * | 2009-04-09 | 2010-10-14 | The University Of Melbourne | Immunogenic composition and uses thereof |
| MX2011012147A (es) | 2009-05-15 | 2012-06-19 | Irx Therapeutics Inc | Inmunoterapia de vacuna. |
| KR101911380B1 (ko) * | 2009-07-24 | 2018-10-25 | 로드아일랜드하스피틀 | 아스파라기닐-β-히드록실라제 발현 종양을 위한 수지상 세포 백신 |
| US20120183518A1 (en) * | 2009-08-24 | 2012-07-19 | Hong Jiang | Assay for determining health of cd8+ t cells |
| AU2010307075B2 (en) | 2009-10-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Granulysin in immunotherapy |
| CN103097543A (zh) | 2009-12-08 | 2013-05-08 | 伊尔克斯治疗有限公司 | 逆转朗格汉斯细胞免疫抑制的方法 |
| US9476029B2 (en) * | 2010-11-13 | 2016-10-25 | Lung-Ji Chang | Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells |
| NL2009102C2 (en) * | 2012-07-02 | 2014-01-06 | Dcprime B V | Method for dc-loading. |
| TWI503414B (zh) * | 2012-07-05 | 2015-10-11 | Fullhope Biomedical Co Ltd | 一種製備專一性ｔ細胞之配方、方法及其配方製備方法 |
| US9744193B2 (en) | 2012-09-06 | 2017-08-29 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
| AU2020203845C1 (en) * | 2012-09-06 | 2022-08-11 | Orbis Health Solutions, Llc | Tumor lysate loaded particles |
| AU2013359392C1 (en) | 2012-12-12 | 2016-12-08 | Orbis Health Solutions, Llc | Compositions and methods for tissue regeneration |
| EP2913394B1 (en) * | 2012-12-18 | 2016-06-22 | Immunicum AB | Co-differentiation and activation of monocytes from allogeneic donors to provide pro-inflammatory dendritic cells |
| CN112891522A (zh) * | 2013-09-05 | 2021-06-04 | 奥比思健康解决方案有限责任公司 | 装载了肿瘤裂解物的微粒 |
| CN103756960A (zh) * | 2013-12-04 | 2014-04-30 | 深圳市合一康生物科技有限公司 | 一种高毒性、高增值能力的人d-cik细胞的专用试剂盒 |
| CN103784950A (zh) * | 2014-01-22 | 2014-05-14 | 北京弘润源生物技术有限公司 | 乳腺癌特异抗原表位多肽负载的树突状细胞疫苗制备及其试剂盒 |
| WO2015134606A1 (en) | 2014-03-05 | 2015-09-11 | Orbis Health Solutions Llc | Vaccine delivery systems using yeast cell wall particles |
| CN103800897B (zh) * | 2014-03-12 | 2017-03-22 | 李金珍 | 一种肿瘤特异抗原表位多肽负载的树突状细胞疫苗制备方法及其试剂盒 |
| ES2817325T3 (es) * | 2014-06-23 | 2021-04-07 | Jw Creagene Inc | Procedimiento de preparación de células dendríticas con aumento de expresión génica específica, y composición para tratar o prevenir enfermedades autoinmunes, conteniendo células dendríticas preparadas utilizando el mismo |
| WO2016145578A1 (en) | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| JP6980650B2 (ja) * | 2015-09-15 | 2021-12-15 | ノースウエスト バイオセラピューティクス，インコーポレイティド | 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法 |
| CN105670994A (zh) * | 2016-02-28 | 2016-06-15 | 深圳爱生再生医学科技有限公司 | Dc诱导剂及其应用 |
| CN105647867A (zh) * | 2016-02-28 | 2016-06-08 | 深圳爱生再生医学科技有限公司 | 诱导树突状细胞成熟的方法和树突状细胞 |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| CN109844100A (zh) * | 2016-09-01 | 2019-06-04 | 株式会社理研免疫再生医学 | 制备天然杀伤t(nkt)细胞刺激性树突细胞的方法及制备含有nkt细胞刺激性树突细胞和nkt细胞的细胞组合物的方法 |
| EP3518942A4 (en) * | 2016-09-29 | 2020-05-27 | Hadasit Medical Research Services&Development Ltd. | DENDRITIC CELL PREPARATIONS, COMPOSITIONS AND METHODS OF USE |
| JP7285828B2 (ja) | 2017-09-05 | 2023-06-02 | トルク セラピューティクス， インコーポレイテッド | 治療用タンパク質組成物ならびにその作製および使用方法 |
| CN109957548B (zh) * | 2017-12-26 | 2022-03-18 | 上海尚泰生物技术有限公司 | 一种基因修饰的树突状细胞疫苗 |
| JP6881332B2 (ja) * | 2018-01-29 | 2021-06-02 | 株式会社三洋物産 | 遊技機 |
| JP6881333B2 (ja) * | 2018-01-29 | 2021-06-02 | 株式会社三洋物産 | 遊技機 |
| JP6881331B2 (ja) * | 2018-01-29 | 2021-06-02 | 株式会社三洋物産 | 遊技機 |
| WO2019183924A1 (en) | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
| JP2021533759A (ja) * | 2018-08-10 | 2021-12-09 | ユーティレックス カンパニー リミテッド | 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法 |
| CN110106145B (zh) * | 2019-06-12 | 2021-02-12 | 蓝莲(杭州)生物科技有限公司 | 一种未成熟树突状细胞培养液及其未成熟树突状细胞的制备方法 |
| WO2021230704A1 (ko) * | 2020-05-15 | 2021-11-18 | 서울대학교 산학협력단 | 지방조직에서 분리된 기질혈관분획의 수지상세포의 활성화 기능을 이용한 면역 반응 증진용 조성물 |
| KR102753583B1 (ko) * | 2021-11-11 | 2025-01-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물 |
| KR102818249B1 (ko) * | 2021-11-11 | 2025-06-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT633929E (pt) | 1992-04-01 | 2004-07-30 | Merix Bioscience Inc | Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios |
| US5788963A (en) | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| CA2286819A1 (en) * | 1997-04-17 | 1998-10-22 | Flossie Wong-Staal | Use of lentiviral vectors for antigen presentation in dendritic cells |
| US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| AU2002326463A1 (en) | 2001-07-25 | 2003-02-17 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
| CN1636229B (zh) * | 2001-09-06 | 2012-12-19 | 西北生物治疗药物公司 | 引发单核树突细胞和t细胞th-1应答的组合物和方法 |
| WO2004000444A1 (en) | 2002-06-19 | 2003-12-31 | Northwest Biotherapeutics, Inc. | Tangential flow filtration devices and methods for leukocyte enrichment |
| AT412145B (de) * | 2002-09-13 | 2004-10-25 | Forsch Krebskranke Kinder | Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen |
| ES2321939T3 (es) * | 2003-02-27 | 2009-06-15 | Northwest Biotherapeutics, Inc. | Generacion de celulas dendriticas a partir de celulas precursoras dendriticas monociticas con gm-csf en ausencia de citoquinas adicionales. |
-
2006
- 2006-12-08 KR KR1020087016423A patent/KR20080109717A/ko not_active Ceased
- 2006-12-08 AU AU2006321794A patent/AU2006321794A1/en not_active Abandoned
- 2006-12-08 CA CA2632263A patent/CA2632263C/en active Active
- 2006-12-08 TW TW095145931A patent/TW200800252A/zh unknown
- 2006-12-08 EP EP06848532A patent/EP1957634A4/en not_active Ceased
- 2006-12-08 JP JP2008544561A patent/JP5954918B2/ja active Active
- 2006-12-08 CN CNA2006800520283A patent/CN101336291A/zh active Pending
- 2006-12-08 WO PCT/US2006/047083 patent/WO2007067782A2/en not_active Ceased
- 2006-12-08 EP EP20196461.6A patent/EP3805367A1/en active Pending
- 2006-12-08 KR KR1020187011878A patent/KR20180049169A/ko not_active Ceased
- 2006-12-08 BR BRPI0619499-0A patent/BRPI0619499A2/pt not_active Application Discontinuation
- 2006-12-08 EP EP16170001.8A patent/EP3072958A1/en not_active Withdrawn
- 2006-12-08 KR KR1020227026051A patent/KR20220113543A/ko not_active Ceased
- 2006-12-08 KR KR1020237044465A patent/KR20240005984A/ko not_active Ceased
- 2006-12-08 US US12/096,419 patent/US20080254537A1/en not_active Abandoned
- 2006-12-08 CN CN201310523196.8A patent/CN103589684A/zh active Pending
- 2006-12-08 RU RU2008122550/13A patent/RU2008122550A/ru not_active Application Discontinuation
- 2006-12-08 KR KR1020157017377A patent/KR20150082688A/ko not_active Ceased
- 2006-12-08 KR KR1020217002605A patent/KR20210013327A/ko not_active Ceased
- 2006-12-11 AR ARP060105446A patent/AR056851A1/es unknown
-
2008
- 2008-06-03 IL IL191930A patent/IL191930A/en active IP Right Grant
- 2008-06-05 CR CR10048A patent/CR10048A/es not_active Application Discontinuation
-
2012
- 2012-06-08 US US13/492,693 patent/US20120244620A1/en active Pending
-
2013
- 2013-08-05 JP JP2013162033A patent/JP2013223517A/ja active Pending
- 2013-11-10 IL IL229348A patent/IL229348B/en active IP Right Grant
-
2016
- 2016-02-26 JP JP2016035257A patent/JP2016105725A/ja not_active Withdrawn
-
2017
- 2017-06-22 JP JP2017122256A patent/JP2017158595A/ja not_active Withdrawn
-
2018
- 2018-12-21 JP JP2018238996A patent/JP2019062904A/ja not_active Withdrawn
-
2021
- 2021-01-04 JP JP2021000066A patent/JP2021045176A/ja not_active Withdrawn
-
2023
- 2023-10-10 JP JP2023175234A patent/JP2023171524A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008122550A (ru) | Композиции и способы индуцирования активации незрелых моноцитарных дендритных клеток | |
| WO2006065495A3 (en) | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens | |
| Bai et al. | Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells | |
| ES2613132T3 (es) | Vacunas terapéuticas contra el cáncer derivadas de una línea celular dendrítica novedosa | |
| CN103201378B (zh) | 用于制备树突细胞的组合物和方法 | |
| ES2621406T3 (es) | Método de inducción y de aceleración de células | |
| WO2009034172A1 (en) | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination | |
| Zhang et al. | Preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cells | |
| EP3770251A1 (en) | Method for producing natural killer cells | |
| CN104946588A (zh) | 一种抗原特异性t淋巴细胞的分离和高效扩增培养方法 | |
| CN104379730B (zh) | 使树突细胞成熟的组合物以及用其制备抗原特异性树突细胞的方法 | |
| JP2018511320A (ja) | 治療およびエピトープマッピング用Ｔ細胞の感作および増殖のためのｉｎ ｖｉｔｒｏ人工リンパ節法 | |
| JP6602377B2 (ja) | 樹状細胞の製造方法、これにより製造された樹状細胞及びその用途 | |
| WO2020027094A1 (ja) | ｉＰＳ細胞を介して再生Ｔ細胞集団を製造する方法 | |
| CN104815323B (zh) | 一种树突状细胞肿瘤疫苗及其制备方法 | |
| EP3173474A1 (en) | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination | |
| Hutten et al. | Ex vivo generation of interstitial and langerhans cell-like dendritic cell subset–based vaccines for hematological malignancies | |
| Chang et al. | Cord blood stem-cell-derived dendritic cells generate potent antigen-specific immune responses and anti-tumour effects | |
| CN109642214A (zh) | 用于有效活化nkt细胞的技术 | |
| KR101440102B1 (ko) | 하이드로젤 코팅과 전기천공법을 이용한 강력한 항원제시세포의 제조방법 | |
| Vichchatorn et al. | Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme | |
| WO2003073827A3 (en) | Methods of modulating dendritic cells using adjuvants | |
| CN116785416A (zh) | 一种树突状细胞外泌体肝癌疫苗制备方法 | |
| Obleukhova et al. | Effect of mature dendritic cells primed with autologous tumor antigens from patients with epithelial ovarian cancer on stimulation of the cytotoxic immune response in culture of mononuclear cells | |
| Gounari et al. | Αn optimized, simplified and clinically approved culture system to produce, in large scale, dendritic cells capable of priming specific T cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100312 |